JPMorgan Reiterates Overweight Rating on Roivant Sciences (ROIV), 'ROIV is on the Analyst Focus List'

JPMorgan analyst Brian Cheng reiterated an Overweight rating and $16.00 price target on Roivant Sciences (NASDAQ: ROIV)

The analyst comments "Earlier this month, we hosted an investor group meeting with ROIV’s CEO, CFO and Head of IR in Boston. Compared to our last dinner with mgmt in NY (note), conversation this time was more focused on mosliciguat, which the company recently unveiled for PH-ILD. The rest of the conversation touched on various topics, from the ongoing LNP litigations to ROIV’s latest efforts on the BD front. Broadly speaking, we think investors remain engaged on the story at this level, and we believe a simple sum-of-the-parts calculation on key levers, such as Immunovant, Priovant, Pulmovant, and cash, should justify upside from the current level. We reiterate our OW, as we believe the stock is equipped with multiple levers that remain overlooked by investors. ROIV is on the Analyst Focus List."

For an analyst ratings summary and ratings history on Roivant Sciences click here. For more ratings news on Roivant Sciences click here.

Shares of Roivant Sciences closed at $11.88 yesterday.

You May Also Be Interested In

• Bernstein SocGen Group Starts Terawulf Inc. (WULF) at Outperform
• Smith-Midland receives Nasdaq notice for late quarterly filing
• Quantinuum raises $1.68 billion in US IPO at $60 per share - Reuters